High-fat diet feeding significantly attenuates anagliptin-induced regeneration of islets of Langerhans in streptozotocin-induced diabetic mice

Diabetology and Metabolic Syndrome

Volumn 7, Issue 1, 2015, Pages

  Shinjo, Takanori ^a   Nakatsu, Yusuke ^b   Iwashita, Misaki ^a   Sano, Tomomi ^c   Sakoda, Hideyuki ^d   Ishihara, Hisamitsu ^e   Kushiyama, Akifumi ^f   Fujishiro, Midori ^d   Nishimura, Fusanori ^a   Asano, Tomoichiro ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b Univ Bordeaux   (France)

^c HIROSHIMA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e NIHON UNIVERSITY   (Japan)

^f INSTITUTE FOR ADULT DISEASES   (Japan)

Author keywords

Anagliptin; DPP 4 inhibitor; High fat diet; Islet of Langerhans; Streptozotocin

Indexed keywords

ANAGLIPTIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; NEUROGENIC DIFFERENTIATION FACTOR; STREPTOZOCIN; TRANSCRIPTION FACTOR MAFA; TRANSCRIPTION FACTOR NKX6.1; TRANSCRIPTION FACTOR PDX 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL REGENERATION; CELL SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UPREGULATION;

EID: 84935038279     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/s13098-015-0047-y     Document Type: Article

References (22)

1. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, et al. Dipeptidyl peptidase 4 inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52:741-50.
2. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55:1695-704.
3. Dalla Man C, Bock G, Giesler PD, Serra DB, Liqueros Saylan M, Foley JE, et al. Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action inresponse to meal investigation in type 2 diabetes. Diabetes Care. 2009;32:14-8.
4. Hayes HL, Moss LG, Schisler JC, Haldeman JM, Zhang Z, Rosenberg PB, et al. Pdx-1 activates islet α- and β-cell proliferation via a mechanism regulated by transient receptor potential cation channels 3 and 6 and extracellular signal-regulated kinases 1 and 2. Mol Cell Biol. 2013;33:4017-29.
5. Gagliardino JJ, Del Zotto H, Massa L, Flores LE, Borelli MI. Pancreatic duodenal homeobox-1 and islet neogenesis-associated protein: a possible combined marker of activateable pancreatic cell precursors. J Endocrinol. 2003;177:249-59.
6. Kawashima S, Matsuoka TA, Kaneto H, Tochino Y, Kato K, Yamamoto K, et al. Effects of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice. Biochem Biophys Res Commun. 2011;404:534-40.
7. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intorelance. J Clin Invest. 2000;106:329-33.
8. Ahrén B. Type 2 diabetes, insulin secretion and beta-cell mass. Curr Mol Med. 2005;5:275-86.
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33:S62-9.
10. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Eshes JA. Islet inflammation impairs in the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda). 2009;24:325-31.
11. Meier JJ, Bonadonna RC. Role of reduced β-cell mass versus impaired β-cell function in the pathogenesis of type 2 diabetes. Diabetes Care. 2013;36:S113-9.
12. Henguin JC, Rahier J. Pancreatic alpha cell mass in European subjects with type 2 diabtes. Diabetologia. 2011;54:1720-5.
13. Ellingsgaard H, Eshes JA, Hammar EB, Van Lommel L, Quintens R, Martens G, et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A. 2008;105:13163-8.
14. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, et al. The dipeptidyl peptidase 4 inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92:1249-55.
15. Shah P, Ardestani A, Dharmadhikari G, Laue S, Schumann DM, Kerr-Conte J, et al. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization. J Clin Endocrinol Metab. 2013;98:E1163-72.
16. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide in the pancreas. Parmacol Ther. 2007;113:546-93.
17. 2+ channel-dependent exocytosis. Cell Metab. 2010;11:543-53.
18. Ravier MA, Rutter GA. Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells. Diabetes. 2005;54:1789-97.
19. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006;116:1802-12.
20. Akiyama M, Liew CW, Lu S, Hu J, Martinez R, Hambro B, et al. X-box binding protein 1 is essential for insulin regulation of pancreatic α-cell function. Diabetes. 2013;62:2439-49.
21. Folli F, Okada T, Perego C, Gunton J, Liew CW, Akiyama M, et al. Altered insulin receptor signaling and β-cell cycle dynamics in type 2 diabetes mellitus. PLoS One. 2011;6, e28050.
22. Kawamori D, Kurpad AJ, Hu J, Liew CW, Shih JL, Ford EL, et al. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab. 2009;9:350-61.